SiRNA (Small interfering Ribonucleic Acid)/anti-cancer drug combined transferring composite supporter and preparation method and application thereof

A composite carrier, anticancer drug technology, applied in drug combinations, antitumor drugs, pharmaceutical formulations, etc., can solve the problems of low transfection efficiency of non-viral vectors, easy to induce immune response, large particles in the delivery system, etc. Cytotoxicity, achieving targeting, increasing the effect of loading

Inactive Publication Date: 2014-02-26
DALIAN NATIONALITIES UNIVERSITY
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] To sum up, the research on non-viral vectors has achieved many gratifying results in recent decades, and now many research groups are doing a lot of research work on the improvement of the corresponding shortcomings of non-viral vectors, but the transformation of non-viral ve...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • SiRNA (Small interfering Ribonucleic Acid)/anti-cancer drug combined transferring composite supporter and preparation method and application thereof
  • SiRNA (Small interfering Ribonucleic Acid)/anti-cancer drug combined transferring composite supporter and preparation method and application thereof
  • SiRNA (Small interfering Ribonucleic Acid)/anti-cancer drug combined transferring composite supporter and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0090] Weigh a certain mass of new-type cationic lipid DDCTMA, dissolve DDCTMA and paclitaxel in 1ml of chloroform at a mass ratio of 200 / 1, after fully dissolving, blow the film with nitrogen, dry in vacuum overnight, add 1ml of ultrapure water at 55°C and place in The paclitaxel liposome (DDCTMA-TAX200 / 1) was prepared in a water bath at 55°C for 2-3 hours, and repeatedly ultrasonically oscillated at 55°C until clarified.

[0091] Compression of siRNA: Sulfate protamine (belonging to cationic polymer) is dissolved in 5% glucose aqueous solution, siRNA and hyaluronic acid (belonging to glycosaminoglycan) are mixed at a mass ratio of 1:1, and the above mixed liquid droplets Add it into protamine sulfate solution, the mass ratio of protamine sulfate to siRNA is 5:1, vortex and oscillate to mix, and incubate at room temperature for 20 minutes to obtain compressed siRNA for later use.

[0092] The paclitaxel liposome and the prepared compressed siRNA were mixed at a mass ratio of ...

Embodiment 2

[0095] Weigh a certain amount of new lipid DDCTMA, and dissolve DDCTMA and paclitaxel in 1ml of chloroform at a mass ratio of 200 / 1. After fully dissolving, add DOPE with a molar ratio of 1 / 1 to DDCTMA, blow film with nitrogen, and vacuum dry Overnight, add 1 ml of ultrapure water at 55°C and place in a water bath at 55°C for 2-3 hours, and repeatedly ultrasonically shake at 55°C until clarified to prepare paclitaxel liposomes (DDCTMA-TAX+D200 / 1).

[0096] Compression of siRNA: Protamine sulfate was dissolved in 5% glucose aqueous solution, protamine sulfate and siRNA were mixed at a mass ratio of 4:1, vortexed and oscillated, incubated at room temperature for 20 minutes, and compressed siRNA was obtained for use.

[0097] Mix paclitaxel liposomes with the prepared compressed siRNA at a mass ratio of 1 / 1, 2 / 1, 3 / 1, 4 / 1, 5 / 1, and 10 / 1, vortex slightly, and incubate at room temperature for 15-20 minutes to obtain Modified composite carrier.

[0098] The composite carrier prepar...

Embodiment 3

[0100] Weigh a certain amount of new lipid DDCTMA, and dissolve DDCTMA and paclitaxel in 1ml of chloroform at a mass ratio of 100 / 1. After fully dissolving, blow the film with nitrogen and dry it in vacuum overnight. °C for 2-3 hours in a water bath, repeated ultrasonic vibration at 55 °C until clarified, and paclitaxel liposomes (DDCTMA-TAX100 / 1) were prepared.

[0101] Compression of siRNA: Dissolve protamine sulfate in 5% glucose aqueous solution, mix siRNA and hyaluronic acid at a mass ratio of 1:1, add the above mixture dropwise to protamine sulfate solution, protamine sulfate The mass ratio of siRNA to siRNA was 2:1, vortexed to mix, and incubated at room temperature for 20 min to obtain compressed siRNA for later use.

[0102] Mix paclitaxel liposomes with the prepared compressed siRNA at a mass ratio of 1 / 1, 4 / 1, 8 / 1, 12 / 1, 16 / 1, and 20 / 1, vortex slightly, and incubate at room temperature for 15-20 minutes to obtain Modified composite carrier.

[0103] The composite ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a siRNA (small interfering Ribonucleic Acid)/anti-cancer drug combined transferring composite supporter and a preparation method and application thereof. The composite supporter comprises a drug liposome and a compressed siRNA in a mass ratio of 20: 1 to 0.5: 1, wherein the drug liposome consists of cationic lipid and a fat soluble medicine in a mass ratio of 200: 1 to 1: 1. According to the preparation method, carbamic acid type cationic lipid is used as a main material for preparing the liposome, the method of compressing a silent gene (siRNA) by a cationic high polymer is used for effectively encapsulating the gene, the targeting and long-circulating modification is performed, and thus a nanoscale novel composite supporter jointly loaded with the anti-cancer drug and the silent gene (siRNA) can be obtained. The preparation method of the composite supporter is simple and efficient; the prepared composite supporter is low in toxicity and high in transfection efficiency; high evaluation effect is obtained from physical characterization and in-vitro biological study.

Description

technical field [0001] The invention relates to a combined transport composite carrier of medicine and gene, in particular to a novel combined transport compound carrier of anticancer drug and compressed siRNA. Background technique [0002] The combined delivery therapy of targeted drugs and genes is a biomedical treatment method that uses carriers to efficiently deliver target drugs and genes to target cells or target tissues to release drugs and genes in a timely manner to achieve synergistic therapeutic goals. Combined delivery of drugs and siRNA in the same carrier system is more effective than delivery of siRNA or drugs alone for combined treatment [1]. At present, the idea of ​​co-transportation has been proposed, and co-transporting drugs and siRNA in the same delivery system is expected to solve the problem of multi-drug resistance that cancer cells are prone to produce. At present, the construction of a safe and efficient carrier for combined transport has become a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61K9/127A61K47/34A61K47/22A61K47/18A61K47/26A61K47/20A61P35/00
Inventor 张树彪张传敏赵轶男崔韶晖陈会英
Owner DALIAN NATIONALITIES UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap